Continuous Manufacturing Platform for Active Pharmaceutical Ingredients (APIs) (Continuous Production of Active Pharmaceutical Ingredients, Tech ID: 19‑020)
Technology Overview: This technology provides a continuous manufacturing platform for producing APIs, replacing traditional batch‑based pharmaceutical processing. The system enables precise control over reaction conditions, residence time, and product quality while improving throughput and reproducibility. Continuous production reduces footprint, energy consumption, and batch variability, aligning with regulatory trends encouraging modernized pharmaceutical manufacturing.
Industry Pain Point: Batch API manufacturing is inefficient, capital‑intensive, and prone to variability.
NJIT Solution: This platform enables continuous, tightly controlled API production, improving efficiency and consistency.
Key Features & Advantages
- Continuous, steady‑state API production
- Improved quality and batch consistency
- Reduced manufacturing footprint and cost
- Regulatory‑aligned advanced manufacturing
Development Stage: TRL 5–6 – Laboratory and pilot‑scale demonstrations completed.
Target Markets
- Pharmaceutical manufacturers
- Contract development and manufacturing organizations (CDMOs)
- Generic drug producers
Market Opportunity
- Global API market (2026): ~$230B
- CAGR: ~6–7%
- Projected market size (2035): ~$380–400B
Commercial & IP Details
Inventor: Kamalesh Sirkar